Karyopharm Therapeutics | KPTI - Operating Profit


Karyopharm Therapeutics reported $-31.28M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Abbott USD 2.25B 73M Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
MacroGenics USD -12.1M 30.74M Dec/2025
Merck USD 6.24B 318M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Novartis USD 4.06B 437M Dec/2025
Novartis USD 4.06B 521M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Takeda JPY 168.82B 479.89B Dec/2025
Tectonic Therapeutic USD -21.52M 374K Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025